source
- Argenx shares tumble 15% after Phase 3 Sjögren’s study of Vyvgart halted for futilityArgenx reported that an independent monitoring board recommended stopping its Phase 3 trial of Vyvgart in Sjögren’s disease due to futility, based on an interim analysis. The decision came earlier…
- Argenx halts Phase 3 Sjögren's trial as celiac disease data brings mixed resultsArgenx disclosed on Thursday that it is ending its Phase 3 trial in Sjögren's syndrome after the study failed to meet its primary endpoint. The decision came alongside the release of encouraging r…